<DOC>
	<DOCNO>NCT00027612</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Irinotecan may make tumor cell sensitive radiation therapy . PURPOSE : This phase I/II trial study side effect irinotecan give together radiation therapy follow irinotecan carmustine see well work treat patient newly-diagnosed glioblastoma multiforme .</brief_summary>
	<brief_title>Irinotecan Plus Radiation Therapy Followed By Chemotherapy Treating Patients With Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety adjuvant irinotecan administer concurrently radiotherapy patient newly diagnose glioblastoma multiforme . - Determine survival patient treat regimen follow irinotecan carmustine . - Assess toxic effect regimen patient . - Determine whether dose irinotecan chosen produce radiosensitizing plasma concentration SN-38 patient . - Assess individual variation response ( toxicity and/or activity ) , pharmacokinetic parameter , and/or biological correlate due genetic difference enzymes involved transport , metabolism , and/or mechanism action irinotecan patient treat regimen . OUTLINE : This pilot , dose-escalation study irinotecan . Patients stratify accord receipt concurrent enzyme-inducing anticonvulsant ( EIACs ) ( yes v ) . - Phase I ( close accrual 3/5/2005 ) : Patients receive carmustine IV 2 hour day 1 course 2-5 irinotecan IV 90 minute ( begin immediately carmustine infusion ) day 1 , 8 , 22 , 29 course 1-5 . Patients also undergo radiotherapy 5 day week 6 week concurrently course 1 . Treatment repeat every 6 week 5 course absence unacceptable toxicity . Cohorts 6 patient receive escalate dos irinotecan recommend dose phase II determine . The recommend dose phase II define dose 2 6 patient experience dose-limiting toxicity .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<criteria>18 year old Histologically confirm newly diagnose grade IV astrocytoma gliosarcoma No oligodendrogliomas/oligoastrocytomas Study entry must occur within 8 week surgery Performance status ECOG 02 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 130,000/mm^3 Bilirubin ≤ 1.5 time upper limit normal ( ULN ) SGOT ≤ 2 time ULN Creatinine ≤ 0.5 mg/dL ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No uncontrolled infection No concurrent malignant disease except superficial skin cancer No major medical problem No prior chemotherapy No prior radiotherapy tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>